Table 2.
Summary of the characteristics of the 13 COVID-19 patients who developed IFIs.
| Characteristics | Results |
|---|---|
| Age (years), mean (median, IQR) | 63.6 (69; 53.5–75) |
| Male sex, n (%) | 9 (69) |
| Risk factors for IFIs, n (%) | 2 (15) |
| Hematologic malignancy | 1 (8) |
| HIV/AIDS | 0 (0) |
| Neutropenia | 0 (0) |
| Immunotherapy | 1 (8) |
| Supplemental oxygen therapy, n (%) | 13 (100) |
| WHO-OSCI score ≥5, n (%) | 8 (62) |
| ICU admission prior to IFI, n (%) | 6 (46) |
| Length of ICU stay prior to IFI (days), mean (median, IQR) | 12 (5; 2–21.5) |
| Length of hospital stay prior to IFI (days), mean (median, IQR) | 28.5 (16.5; 7.75–40.75) |
| Time since COVID-19 onset (days), mean (median, IQR) | 45.7 (39.5; 13–65) |
| Cumulative prednisone-equivalent steroid dose prior to IFI (mg), mean (median, IQR) | 1028.5 (630; 447–1433) |
| Duration of steroid therapy prior to IFI (days), mean (median, IQR) | 38.5 (31.5; 15–58.25) |
| Lymphocytopenia (<1000 cells/µL), n (%) | 9 (69) |
| CD4+ count < 200 cells/µL | 5/8 (63) |
| Overall length of hospital stay (days), mean (median, IQR) | 49.5 (41; 23–69.5) |
| Overall mortality, n (%) | 3 (23) |